GLOBUS MEDICAL INC - A (GMED) Stock Overview
NYSE:GMED - US3795772082 - Common Stock
GMED Key Statistics, Chart & Performance
The current stock price of GMED is 61.13 USD. In the past month the price increased by 16.15%. In the past year, price decreased by -15.91%.
GMED Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 26.81 | 228.64B | ||
| ISRG | INTUITIVE SURGICAL INC | 58.86 | 169.86B | ||
| BSX | BOSTON SCIENTIFIC CORP | 37.37 | 156.70B | ||
| SYK | STRYKER CORP | 30.32 | 148.97B | ||
| MDT | MEDTRONIC PLC | 16.63 | 117.82B | ||
| BDX | BECTON DICKINSON AND CO | 13.4 | 54.82B | ||
| IDXX | IDEXX LABORATORIES INC | 53.87 | 51.76B | ||
| EW | EDWARDS LIFESCIENCES CORP | 31.61 | 47.69B | ||
| RMD | RESMED INC | 28.84 | 40.32B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.82 | 33.66B | ||
| DXCM | DEXCOM INC | 44.16 | 29.44B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.51 | 26.56B |
Related stock screener links
About GMED
Company Profile
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The company is headquartered in Audubon, Pennsylvania and currently employs 5,300 full-time employees. The company went IPO on 2012-03-08. The firm offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the conditions affecting the spine, including degenerative conditions, deformities, tumors, and trauma. The company provides solutions that facilitate both open and minimally invasive surgery techniques. The company includes traditional fusion implants, such as pedicle screws and rod systems, and others. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip.
Company Info
GLOBUS MEDICAL INC - A
2560 General Armistead Ave
Audubon PENNSYLVANIA 19403 US
CEO: David M. Demski
Employees: 5300
Phone: 16109301800
GLOBUS MEDICAL INC - A / GMED FAQ
What is the stock price of GLOBUS MEDICAL INC - A today?
The current stock price of GMED is 61.13 USD. The price decreased by -0.62% in the last trading session.
What is the ticker symbol for GLOBUS MEDICAL INC - A stock?
The exchange symbol of GLOBUS MEDICAL INC - A is GMED and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is GMED stock listed?
GMED stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for GLOBUS MEDICAL INC - A stock?
21 analysts have analysed GMED and the average price target is 84.2 USD. This implies a price increase of 37.73% is expected in the next year compared to the current price of 61.13. Check the GLOBUS MEDICAL INC - A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GLOBUS MEDICAL INC - A worth?
GLOBUS MEDICAL INC - A (GMED) has a market capitalization of 8.26B USD. This makes GMED a Mid Cap stock.
How many employees does GLOBUS MEDICAL INC - A have?
GLOBUS MEDICAL INC - A (GMED) currently has 5300 employees.
What are the support and resistance levels for GLOBUS MEDICAL INC - A (GMED) stock?
GLOBUS MEDICAL INC - A (GMED) has a support level at 53.02 and a resistance level at 61.16. Check the full technical report for a detailed analysis of GMED support and resistance levels.
Is GLOBUS MEDICAL INC - A (GMED) expected to grow?
The Revenue of GLOBUS MEDICAL INC - A (GMED) is expected to grow by 13.98% in the next year. Check the estimates tab for more information on the GMED EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy GLOBUS MEDICAL INC - A (GMED) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GMED, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GMED, evaluating the profitability, health, valuation and growth aspects
- GLOBUS MEDICAL INC - A (GMED) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GLOBUS MEDICAL INC - A (GMED) Sales and EPS estimates to see what analysts future expectations are.
- GLOBUS MEDICAL INC - A (GMED) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GLOBUS MEDICAL INC - A (GMED) Insider and Institutional Ownership to learn about the owners and their transactions.
- GLOBUS MEDICAL INC - A (GMED) Stock Chart to make your own analysis
- GLOBUS MEDICAL INC - A (GMED) Latest news and press-releases to stay up to date.
Does GLOBUS MEDICAL INC - A (GMED) stock pay dividends?
GMED does not pay a dividend.
When does GLOBUS MEDICAL INC - A (GMED) report earnings?
GLOBUS MEDICAL INC - A (GMED) will report earnings on 2025-11-03, after the market close.
What is the Price/Earnings (PE) ratio of GLOBUS MEDICAL INC - A (GMED)?
The PE ratio for GLOBUS MEDICAL INC - A (GMED) is 19.04. This is based on the reported non-GAAP earnings per share of 3.21 and the current share price of 61.13 USD. Check the full fundamental report for a full analysis of the valuation metrics for GMED.
What is the Short Interest ratio of GLOBUS MEDICAL INC - A (GMED) stock?
The outstanding short interest for GLOBUS MEDICAL INC - A (GMED) is 4.26% of its float. Check the ownership tab for more information on the GMED short interest.
GMED Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to GMED. When comparing the yearly performance of all stocks, GMED is a bad performer in the overall market: 80.39% of all stocks are doing better.
GMED Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to GMED. GMED scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
GMED Financial Highlights
Over the last trailing twelve months GMED reported a non-GAAP Earnings per Share(EPS) of 3.21. The EPS increased by 21.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 13.58% | ||
| ROA | 7.19% | ||
| ROE | 8.3% | ||
| Debt/Equity | 0 |
GMED Forecast & Estimates
21 analysts have analysed GMED and the average price target is 84.2 USD. This implies a price increase of 37.73% is expected in the next year compared to the current price of 61.13.
For the next year, analysts expect an EPS growth of 4.19% and a revenue growth 13.98% for GMED